approval · primary record
LISDEXAMFETAMINE DIMESYLATE
2 approval events · latest 2026-04-23
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-04-23 |
| Approval events | 2 |
| Brand | VYVANSE |
| Sponsor | TAKEDA PHARMS USA |
| Route | ORAL |
Approval history
2 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-04-23 | FDA | NDA | VYVANSE | TAKEDA PHARMS USA | ORAL |
| 2025-12-22 | FDA | NDA | ARYNTA | AZURITY | ORAL |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:32:06.944Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:lisdexamfetamine-dimesylate
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Lisdexamfetamine Dimesylate · compound